Carlsmed (CARL) AI Spine Surgery Planning: Lead Time Cut Over 30%

Carlsmed (CARL) said on its August 5, 2026 second-quarter earnings call that once a surgeon approves an AI-generated surgical plan, the complete set of implants and instruments reaches the hospital in about a week. Gross margin expanded 340 basis points year over year in the same quarter, but management attributed that expansion to lower contract manufacturing costs and to product mix as well.[1]

What Carlsmed sells and how the AI planning works

Carlsmed, Inc. (CARL) is a medical technology company focused on spine surgery. Its revenue comes from custom implants and single-use instrument kits sold to hospitals on a per-procedure basis. The product is a digital surgery platform called aprevo. Before a lumbar or cervical fusion procedure, the spine surgeon gives the system the patient's anatomical imaging and the surgical objectives, and the system uses AI to generate a three-dimensional surgical plan. Only after the surgeon personally reviews and approves that plan does Carlsmed manufacture the implants and instruments fitted to that one patient and ship them to the operating room as a kit.[1] The platform carries all of the company's revenue; in the second quarter, lumbar procedures were about 90% of revenue and cervical procedures about 10%.[1]

How the disclosure developed

Public disclosure begins with the February 25, 2026 call. The platform was already in use at scale in lumbar and cervical procedures, and the company gave three readings at once: 101 new surgeon users added in 2025, a 25% lead-time reduction to six business days, and a retrospective cohort study in which adult spinal deformity patients receiving a personalized lumbar implant had a 74% lower re-operation rate than a separately published cohort receiving conventional stock implants.[3]

The turn came on May 5, 2026, when the same production improvement was written into a financial explanation for the first time. Management explained gross margin expansion as stable revenue per procedure combined with efficiency improvements in the digital production system.[2] Postoperative outcome analysis was folded into the same workflow in that period, extending the platform past the operation itself. By August 5, 2026, the delivery cadence had settled at about a week, and the same efficiency improvement appeared again in the explanation for gross margin expansion.[1]

The latest quarter's numbers measure different things

The roughly one-week cadence covers the whole path from surgeon approval of the plan to kit delivery at the hospital, and the company credits technology investment and operational execution rather than the planning algorithm specifically.[1] The surgeon user base grew more than 60% year over year, which measures the breadth of adoption; the company did not disclose the total number of users or state how an active surgeon is counted.[1] Second-quarter revenue grew 57% year over year, which management attributed to gains in lumbar share, higher volume from onboarded surgeons and the rollout of cervical products.[1] The three are measured on different bases and cannot corroborate one another.

Where the workflow reaches the financials first: gross profit

Once a plan takes shape inside the system it drives production directly, cutting out manual design work and rework in between. In the first quarter, lead time was reduced by more than 30% to six business days from surgeon approval to delivery of the complete kit,[2] so the same capacity and fixed investment can carry more procedures and unit manufacturing cost is spread thinner. Management listed efficiency improvements in the digital production system among the reasons for gross margin expansion in two consecutive quarters: 77.1% gross margin in the first quarter, an expansion of 220 basis points year over year,[2] and another 340 basis points of year-over-year expansion in the second.[1]

That relationship can only be stated as directional. In the first quarter, the efficiency improvement was listed alongside stable revenue per procedure;[2] in the second, it was listed alongside lower per-unit contract manufacturing costs and a change in product mix, and the company did not size any of these items.[1] The AI planning step itself has never been measured on its own. Implant design, the production system and commercial execution all sit inside the same number.

What is confirmed and what is not

What can be confirmed is that Carlsmed has made the cadence from plan design to personalized production repeatable, and that it named that chain in both of its gross margin explanations. Whether the chain can keep pushing gross margin higher has become the main variable in watching this business. What is not confirmed is how much it contributed. Only if the company breaks gross margin expansion out by driver, or discloses the unit cost of the planning and production steps within a single procedure, can the effect of digital production efficiency be measured apart from the other two factors.

Application assessment

• aprevo Personalized Surgery Platform | Business position: Core business | Deployment stage: Limited production | Scope: Multiple businesses or regions | Value type: Revenue growth

Sources

[1] Drillr · Carlsmed, Inc. (CARL) · 2026-08-05 · Earnings call

Original: Gross margin expanded 340 basis points year over year as decreased contract manufacturer costs on a per unit basis and continued efficiency improvements in our Prevost Digital Production System more than offset the impact of product sales mix.

[2] Drillr · Carlsmed, Inc. (CARL) · 2026-05-05 · Earnings call

Original: Operationally, we continue to leverage our investments in technology to further drive production efficiencies. reducing lead time by more than 30% to six business days in the quarter and delivering more than 200 basis points of margin expansion year over year.

[3] Drillr · Carlsmed, Inc. (CARL) · 2026-02-25 · Earnings call

Original: Two-year data from a retrospective cohort study published in the Global Spine Journal showed a 74% reduction in re-operation rates among adult spinal deformity patients receiving a Prevo lumbar implant as compared to a separately published patient cohort receiving conventional stock implants.